Literature DB >> 28889257

Evaluation of auditory and cochlear functions in ankylosing spondylitis patients according to the site of involvement.

Duran Karataş1, İsmail Doğan2, Adnan Ekinci3, Abdurrahman Yetiş3, Müge Özcan3.   

Abstract

Ankylosing spondylitis (AS) is a chronic systemic inflammatory disease of unknown origin with a prevalence rate about 1% in the population. Audiovestibular dysfunction is encountered in AS and sensorineural hearing loss is the most common form. The present study aimed to evaluate auditory and cochlear function in AS patients according to the site of involvement. A total of 47 patients followed for AS in the rheumatology outpatient clinic and 30 healthy controls were enrolled in the study. Subgroups of AS were identified according to the site of involvement. The participants underwent complete otolaryngological examination together with audiometry, otoacoustic emission and tympanometry tests. Disease Activity Index (BASDAI) was determined in the AS group. Hearing loss was detected in seven patients (15%) in the AS group and in four subjects (8%) in the control group. There was statistically significant difference between the patient and control groups in terms of mean bone conduction hearing level at 4000 hertz (Hz) in the right and left ears (p = 0.028, p = 0.049). There was no significant difference between the subgroups of AS in terms of overall auditory and cochlear functions. No correlation was determined between auditory values and Disease Activity Index and CRP (p > 0.05 for all). Our results reveal that AS has minimal effect on auditory and cochlear functions. The effects of subgroups of AS on auditory functions were comparable. The authors concluded that BASDAI and CRP are not convenient in monitoring auditory functions of AS patients.

Entities:  

Keywords:  Ankylosing spondylitis; Disease Activity Index; Hearing loss; Otoacoustic emission

Mesh:

Year:  2017        PMID: 28889257     DOI: 10.1007/s00405-017-4733-2

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  17 in total

Review 1.  Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: a literature review.

Authors:  J Ruof; G Stucki
Journal:  J Rheumatol       Date:  1999-04       Impact factor: 4.666

2.  Cochleovestibular dysfunction in ankylosing spondylitis.

Authors:  Selim S Erbek; H Seyra Erbek; Sema Yilmaz; Ozgul Topal; Eftal Yucel; Levent N Ozluoglu
Journal:  Audiol Neurootol       Date:  2006-06-21       Impact factor: 1.854

3.  Classification criteria for spondyloarthropathies.

Authors:  Ozgur Akgul; Salih Ozgocmen
Journal:  World J Orthop       Date:  2011-12-18

Review 4.  Otorhinolaryngologic complications of rheumatic diseases.

Authors:  J Kovarsky
Journal:  Semin Arthritis Rheum       Date:  1984-11       Impact factor: 5.532

5.  Audiovestibular manifestations in patients with ankylosing spondylitis.

Authors:  Juan C Amor-Dorado; Maria P Barreira-Fernandez; Tomas R Vazquez-Rodriguez; Ines Gomez-Acebo; Jose A Miranda-Filloy; Teresa Diaz de Teran; Javier Llorca; Miguel A Gonzalez-Gay
Journal:  Medicine (Baltimore)       Date:  2011-03       Impact factor: 1.889

6.  Audiovestibular disorders in patients with ankylosing spondylitis.

Authors:  Carolina Casellini; Gustavo Citera; Marcos Rosemffet; Santiago Ruggeri; Andrea Saviotti; José A Maldonado Cocco
Journal:  J Clin Rheumatol       Date:  2005-04       Impact factor: 3.517

7.  Evaluation of hearing loss in patients with ankylosing spondylitis.

Authors:  A Eryilmaz; M Dagli; H Karabulut; F Sivas Acar; E Erkol Inal; C Gocer
Journal:  J Laryngol Otol       Date:  2006-11-24       Impact factor: 1.469

8.  Management and evaluation of extra-articular manifestations in spondyloarthritis.

Authors:  Irene E van der Horst-Bruinsma; Michael T Nurmohamed
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-12       Impact factor: 5.346

9.  Serum nitric oxide, catalase, superoxide dismutase, and malondialdehyde status in patients with ankylosing spondylitis.

Authors:  Salih Ozgocmen; Sadik Sogut; Ozge Ardicoglu; Ersin Fadillioglu; Irfan Pekkutucu; Omer Akyol
Journal:  Rheumatol Int       Date:  2003-06-17       Impact factor: 2.631

10.  Evaluation of the protective effect of Beta glucan on amikacin ototoxicity using distortion product otoacoustic emission measurements in rats.

Authors:  Tuba Bayindir; Aliye Filiz; Mustafa Iraz; Serdar Kaya; Mehmet Tan; Mahmut Tayyar Kalcioglu
Journal:  Clin Exp Otorhinolaryngol       Date:  2013-03-08       Impact factor: 3.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.